16:38 EDT 4D Molecular (FDMT) sees cash, equivalents funding planned operations into 2028
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FDMT:
- 4D Molecular announces RMAT designation granted by FDA for 4D-150 for DME
- Biotech stocks slide as Marks resignation seen being negative for sector
- BMO says Peter Marks resignation ‘significant negative’ for biotech
- 4D Molecular price target lowered to $40 from $42 at BofA
- 4D Molecular announces first patients enrolled in 4FRONT-1 Phase 3 trial